Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 20

1.

MicroRNA-34a inhibits glioblastoma growth by targeting multiple oncogenes.

Li Y, Guessous F, Zhang Y, Dipierro C, Kefas B, Johnson E, Marcinkiewicz L, Jiang J, Yang Y, Schmittgen TD, Lopes B, Schiff D, Purow B, Abounader R.

Cancer Res. 2009 Oct 1;69(19):7569-76. doi: 10.1158/0008-5472.CAN-09-0529.

2.

Targeting strategies on miRNA-21 and PDCD4 for glioblastoma.

Wang G, Wang JJ, Tang HM, To SS.

Arch Biochem Biophys. 2015 Aug 15;580:64-74. doi: 10.1016/j.abb.2015.07.001. Review.

PMID:
26142886
3.

MicroRNA-34a and its target genes: Key factors in cancer multidrug resistance.

Ghandadi M, Sahebkar A.

Curr Pharm Des. 2016;22(7):933-9. Review.

PMID:
26648462
4.

microRNA-34a as a Therapeutic Agent against Human Cancer.

Saito Y, Nakaoka T, Saito H.

J Clin Med. 2015 Nov 16;4(11):1951-9. doi: 10.3390/jcm4111951. Review.

5.

MicroRNAs in cancer: glioblastoma and glioblastoma cancer stem cells.

Brower JV, Clark PA, Lyon W, Kuo JS.

Neurochem Int. 2014 Nov;77:68-77. doi: 10.1016/j.neuint.2014.06.002. Review.

6.

Functional roles of enhancer of zeste homolog 2 in gliomas.

Yin Y, Qiu S, Peng Y.

Gene. 2016 Jan 15;576(1 Pt 2):189-94. doi: 10.1016/j.gene.2015.09.080. Review.

PMID:
26435191
7.

Biological basis of personalized anticoagulation in cancer: oncogene and oncomir networks as putative regulators of coagulopathy.

D'Asti E, Rak J.

Thromb Res. 2016 Apr;140 Suppl 1:S37-43. doi: 10.1016/S0049-3848(16)30096-2. Review.

PMID:
27067976
8.

MicroRNA-34a: a potential therapeutic target in human cancer.

Li XJ, Ren ZJ, Tang JH.

Cell Death Dis. 2014 Jul 17;5:e1327. doi: 10.1038/cddis.2014.270. Review.

9.

HPV-p53-miR-34a axis in HPV-associated cancers.

Chen J, Zhao KN.

Ann Transl Med. 2015 Dec;3(21):331. doi: 10.3978/j.issn.2305-5839.2015.09.39. Review.

10.

Biological mechanisms of glioma invasion and potential therapeutic targets.

Tysnes BB, Mahesparan R.

J Neurooncol. 2001 Jun;53(2):129-47. Review.

PMID:
11716066
11.

MicroRNA and extracellular vesicles in glioblastoma: small but powerful.

Rooj AK, Mineo M, Godlewski J.

Brain Tumor Pathol. 2016 Apr;33(2):77-88. doi: 10.1007/s10014-016-0259-3. Review.

PMID:
26968172
12.

The emerging role of MMP14 in brain tumorigenesis and future therapeutics.

Ulasov I, Yi R, Guo D, Sarvaiya P, Cobbs C.

Biochim Biophys Acta. 2014 Aug;1846(1):113-20. doi: 10.1016/j.bbcan.2014.03.002. Review.

PMID:
24657728
13.

Is miR-34a a Well-equipped Swordsman to Conquer Temple of Molecular Oncology?

Farooqi AA, Fayyaz S, Shatynska-Mytsyk I, Javed Z, Jabeen S, Yaylim I, Gasparri ML, Panici PB.

Chem Biol Drug Des. 2016 Mar;87(3):321-34. doi: 10.1111/cbdd.12634. Review.

PMID:
26259537
14.

miR-34: from bench to bedside.

Agostini M, Knight RA.

Oncotarget. 2014 Feb 28;5(4):872-81. Review.

15.

Targeting adaptive glioblastoma: an overview of proliferation and invasion.

Xie Q, Mittal S, Berens ME.

Neuro Oncol. 2014 Dec;16(12):1575-84. doi: 10.1093/neuonc/nou147. Review.

16.

Emergence of miR-34a in radiation therapy.

Lacombe J, Zenhausern F.

Crit Rev Oncol Hematol. 2017 Jan;109:69-78. doi: 10.1016/j.critrevonc.2016.11.017. Review.

PMID:
28010900
17.

Glioblastoma--a moving target.

Westermark B.

Ups J Med Sci. 2012 May;117(2):251-6. doi: 10.3109/03009734.2012.676574. Review.

18.

MicroRNA and brain tumors: a cause and a cure?

Mathupala SP, Mittal S, Guthikonda M, Sloan AE.

DNA Cell Biol. 2007 May;26(5):301-10. Review.

19.

Notching on Cancer's Door: Notch Signaling in Brain Tumors.

Teodorczyk M, Schmidt MH.

Front Oncol. 2015 Jan 5;4:341. doi: 10.3389/fonc.2014.00341. Review.

20.

Stem cells and the origin of gliomas: A historical reappraisal with molecular advancements.

Levy ML, Ho AL, Hughes S, Menon J, Jandial R.

Stem Cells Cloning. 2009 Jan 20;1:41-7. Review.

Items per page

Supplemental Content

Support Center